Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging

Cancer Research

Volumn 60, Issue 15, 2000, Pages 4211-4215

  Guttinger, M ^a   Guidi, F ^a   Chinol, M ^a   Reali, E ^a   Veglia, F ^a   Viale, G ^a   Paganelli, G ^a   Corti, A ^a   Siccardi, A G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; CD3 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; FEMALE; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD3; ANTIGENS, NEOPLASM; AVIDIN; BIOTIN; BIOTINYLATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FIBROSARCOMA; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033870884     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tumour immunology: False hopes-new horizons?
2. T cell defined tumor antigens
3. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
4. Cancer tumor antigens
5. Cancer immunotherapy: Synthetic and natural peptides in the balance
6. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression
7. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
8. TAP off- tumors on
9. Constitutive IL- 10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1
10. Monoclonal antibody-based therapy
11. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins
12. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation
13. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma
14. Three-step tumor targeting via biotin-avidin interaction as a versatile system to elicit T cell mediated, non MHC restricted cytotoxic activity against neoplastic cells
15. Host resistance directed selectively against H2-deficient lymphoma variants
16. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor α
17. Identification of a monoclonal antibody specific for a murine T3 polypeptide
18. Indium-11l-labeled lymphocytes in man
19. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen positive patients
20. In vivo imaging of chromogranin A positive endocrine tumors by three-step monoclonal antibody targeting
21. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
22. Clinical application of the avidin-biotin system for tumor targeting
23. Potential of the avidin-biotin system for diagnostic application
24. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor α in mouse models
25. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma
26. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain
27. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
28. Single chain lg/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity
29. Tumor-specific T-bodies: Towards clinical application